ClinicalTrials.gg
CompletedNCT03421652Updated Aug 4, 2023Results posted

Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo

A Phase 2 interventional study of Nivolumab and Radiation in Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 and Stage IV Bladder Urothelial Carcinoma AJCC v7, sponsored by Barbara Ann Karmanos Cancer Institute. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-04.

Sponsored by Barbara Ann Karmanos Cancer Institute · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This phase II trial studies how well nivolumab works with radiation therapy in treating patients with urothelial bladder cancer that has spread from its original site of growth to nearby tissues or lymph nodes and are ineligible for chemotherapy. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving nivolumab and radiation therapy may work better in treating patients with urothelial bladder cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To compare the 12-month rate of progression-free survival (PFS) achieved with the combination of nivolumab, a programmed death (PD-1) inhibitor, and radiation therapy in localized/locally advanced urothelial cancer patients, who are chemotherapy ineligible, to a historical control reference 12-month PFS rate.

SECONDARY OBJECTIVES:

I. To assess the toxicity of concurrent nivolumab and radiation therapy in urothelial cancer.

II. To determine overall response rate (ORR). III. To determine metastasis-free survival (MFS). IV. To determine overall survival (OS). V. To evaluate the quality of life and bladder functioning during and after the therapy.

VI. To explore the relationships of PD-1 expression, PDL-1 expression, and the Th1/Th2 cytokine ratio to clinical outcomes (response, PFS, MFS, and OS).

OUTLINE:

Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 14 days (2 weeks) for up to 14 courses (6 months) in the absence of disease progression or unacceptable toxicity. Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.

After completion of study treatment, patients are followed up every 3 months for 12 months.

02

Conditions studied

  • Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage IV Bladder Urothelial Carcinoma AJCC v7
03

In context

Lead sponsor

Barbara Ann Karmanos Cancer Institute is the lead sponsor of 161 studies on the registry; 19 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Localized urothelial cancer of bladder with presence of transitional cell carcinoma (TCC) component; mixed histologies are allowed Clinical or pathologic stage T2 -T4 disease including T4a and 4b if feasible to treat with radiation therapy Locoregional lymph node are permitted but patients with distant metastases are ineligible; imaging to evaluate for distant metastases should consist of a minimum of computed tomography (CT)/magnetic resonance imaging (MRI) of abdomen/pelvis or CT urogram and a chest x-ray (CXR) or CT chest; patients for which there is clinical suspicion or symptoms of bone metastasis should have a bone scan completed to rule out metastatic disease prior to enrollment on study Agreeable to consider radiation therapy (RT) for the urothelial cancer: patients have to be evaluated by a radiation oncologist and deemed to be candidates for RT

The patients must not be candidates for chemotherapy due to at least one of the following reasons:

  • Performance status of 2
  • =\< 60 ml/min as calculated by the Cockcroft-Gault formula
  • Cardiac disease such as (NYHA) class III or IV heart failure or cardiac ischemia within the last 12 months, grade 2 or greater neuropathy, or other comorbidities based on which patient is not considered a candidate for chemotherapy Alkaline phosphatase =\< 3 x (AST) =\< 3 x upper limit of normal Alanine aminotransferase (ALT) =\< 3 x upper limit of normal \< 1.5 x upper limit of normal (ULN) >= 1500/mm\^3 >= 9 g/dL >= 100 K/mm\^3 Performance score (PS) of 0-2 by Zubrod score of 12 months Willingness to sign Patients cannot have active disease or conditions Serum creatinine =\< 1.5 X institutional ULN or creatinine clearance > 40 ml/min as calculated by the Cockcroft-Gault formula In females with , or men with partners of child bearing potential, willingness to use adequate for a minimum duration of 155 days in females and 215 days in males, after last dose of nivolumab Maximal tumor resection has been performed as feasible

Exclusion criteria

Exclusion Criteria:

  • The subject has received cytotoxic chemotherapy (including cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) for urothelial cancer within 4 weeks, or intravesical Bacillus Calmette-Guerin (BCG) within 6 weeks of the first dose of study treatment Prior treatment with any or PDL-1 inhibitor

The subject has received therapeutic radiation:

  • To the bladder/prostate/rectum pelvis
  • To any other site(s) within 28 days of the first dose of study treatment Obstructive renal failure that is not relieved with stents or nephrostomy tube/s The subject has received any other type of investigational agent within 28 days before the first dose of study treatment doses greater than an equivalent of prednisone 10 mg daily The subject has (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test results at screening >= 2 x the laboratory Uncontrolled hematuria

The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

  • Cardiovascular disorders such as uncontrolled arrhythmias or uncontrolled congestive heart failure
  • Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:

    • Any of the following at the time of screening

      • Active peptic ulcer disease,
      • Active inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis
    • Any of the following within 6 months before the first dose of study treatment:

      • History of abdominal fistula
      • Bowel perforation The subject has a previously identified allergy or to components of the study treatment formulation The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee Presence of another invasive , which required systemic therapy within 12 months of protocol enrollment, except for resected skin cancers or prostate cancer that is in remission Pregnant or nursing women Patient is a candidate for radical cystectomy as a potentially curative option. The patient may not be a candidate for radical cystectomy due to any of the following reasons: comorbidities, patient preference, or physician discretion. Patients with inherited syndromes associated with hypersensitivity to ionizing radiation (e.g., ataxia-telangiectasia, Nijmegen breakage syndrome)
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment (nivolumab, radiation therapy)

    Given IV

    Drug: Nivolumab · Radiation: Radiation

Interventions

  • Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days (2 weeks) for up to 14 courses (6 months) in the absence of disease progression or unacceptable toxicity. Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.

    Also known as: 946414-94-4, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo

  • RadiationRadiation

    Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS distribution will be summarized with the Kaplan-Meier (K-M) survivorship estimate. A graph of the K-M curve for PFS will be generated along with the Hall-Wellner 90% confidence band, and a display of the number of patients at risk at several time points, below the X-axis. Summary statistics (12-month PFS rate, median PFS, etc.) will be calculated from the K-M life table, each one with its respective 90% confidence interval (CI).

    Time frame: From date of registration to date of first documented disease relapse/progression, or death from urothelial cancer whichever occurs first, assessed up to 12 months

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR will be estimated among all patients. Frequency distributions of best response will be generated. The point estimate of the ORR will be computed, along with its 95% (Wilson type) CI.

    Time frame: Up to 12 months

  2. Metastasis-free Survival (MFS)

    MFS will be calculated as a rate at 1 year with a 90% confidence interval from the K-M life tables.

    Time frame: From registration to the appearance of metastases or cancer related death, assessed up to 12 months

  3. Overall Survival (OS)

    Summary statistics of OS will be calculated from the K-M life tables. K-M graphs of the censored OS distributions will also be generated.

    Time frame: From date of registration to death or last follow up, assessed up to 36 months

  4. Quality of Life (QOL) and Bladder Functioning Questionnaires Assessment

    The QOL score will be measured pre therapy, during therapy and after therapy to compare the changes.

    Time frame: Up to 12 months

  5. PD-1 and PDL-1 Expression Analysis Using Immunohistochemistry (IHC)

    PD-1 status will be checked on pre-therapy tumor tissue and will be correlated with the primary endpoint. Also, the PDL-1 status will be checked on pre-therapy tumor tissue and will be correlated with the primary endpoint.

    Time frame: Up to 12 months

  6. Th1/Th2 Cytokine Ratio Analysis

    The continuous markers (e.g., tumor infiltrating lymphocyte \[TIL\]s, Th1/Th2 cytokine ratio, etc.) will be summarized with standard descriptive statistics. These descriptive analyses of the serum markers will be performed for each time point at which the each marker is determined. Response (CR/PR vs not) will be modeled as a function of a dichotomized version of pre-study the continuous (ungrouped) markers (e.g., TILs from tissue, and the Th1/Th2 cytokine ratio from serum). The statistical goal of these exploratory analyses is to obtain the point and 95% CI estimates of the OR, and to simply determine the direction and approximate magnitude of these associations for use in planning a subsequent study. Censored PFS will be modeled as a function of a dichotomized version of the continuous (ungrouped) markers (e.g., TILs from tissue, and the Th1/Th2 cytokine ratio using Cox modelling strategy.

    Time frame: Up to 12 months

07

Results

Posted Aug 4, 2023

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Nivolumab, Radiation Therapy)
Started20
Completed20
Not completed0

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS distribution will be summarized with the Kaplan-Meier (K-M) survivorship estimate. A graph of the K-M curve for PFS will be generated along with the Hall-Wellner 90% confidence band, and a display of the number of patients at risk at several time points, below the X-axis. Summary statistics (12-month PFS rate, median PFS, etc.) will be calculated from the K-M life table, each one with its respective 90% confidence interval (CI).

Time frame:
From date of registration to date of first documented disease relapse/progression, or death from urothelial cancer whichever occurs first, assessed up to 12 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsTreatment (Nivolumab, Radiation Therapy)
Progression-free Survival (PFS)11.4 (7.5 to 23.7)
SecondaryOverall Response Rate (ORR)

ORR will be estimated among all patients. Frequency distributions of best response will be generated. The point estimate of the ORR will be computed, along with its 95% (Wilson type) CI.

Time frame:
Up to 12 months
Reported as:
Number · percentage of response at 12 months
Overall Response Rate (ORR)
percentage of response at 12 monthsTreatment (Nivolumab, Radiation Therapy)
Overall Response Rate (ORR)65.0 (43.3 to 81.8)
SecondaryMetastasis-free Survival (MFS)

MFS will be calculated as a rate at 1 year with a 90% confidence interval from the K-M life tables.

Time frame:
From registration to the appearance of metastases or cancer related death, assessed up to 12 months
Reported as:
Number · % of patients metastases-free at 1 year
Metastasis-free Survival (MFS)
% of patients metastases-free at 1 yearTreatment (Nivolumab, Radiation Therapy)
Metastasis-free Survival (MFS)63 (41 to 84)
SecondaryOverall Survival (OS)

Summary statistics of OS will be calculated from the K-M life tables. K-M graphs of the censored OS distributions will also be generated.

Time frame:
From date of registration to death or last follow up, assessed up to 36 months
Reported as:
Median · months
Overall Survival (OS)
monthsTreatment (Nivolumab, Radiation Therapy)
Overall Survival (OS)15.6 (9.1 to 26.1)
SecondaryQuality of Life (QOL) and Bladder Functioning Questionnaires Assessment

The QOL score will be measured pre therapy, during therapy and after therapy to compare the changes.

Time frame:
Up to 12 months

No measurements were reported for this outcome.

SecondaryPD-1 and PDL-1 Expression Analysis Using Immunohistochemistry (IHC)

PD-1 status will be checked on pre-therapy tumor tissue and will be correlated with the primary endpoint. Also, the PDL-1 status will be checked on pre-therapy tumor tissue and will be correlated with the primary endpoint.

Time frame:
Up to 12 months
Reported as:
Number · % of patients progression-free at 1 year
PD-1 and PDL-1 Expression Analysis Using Immunohistochemistry (IHC)
% of patients progression-free at 1 yearTreatment (Nivolumab, Radiation Therapy)
PD-1 <544 (16 to 73)
PD-1 =>535 (0 to 80)
PD-L1 <536 (11 to 62)
PD-L1 =>555 (14 to 95)
SecondaryTh1/Th2 Cytokine Ratio Analysis

The continuous markers (e.g., tumor infiltrating lymphocyte \[TIL\]s, Th1/Th2 cytokine ratio, etc.) will be summarized with standard descriptive statistics. These descriptive analyses of the serum markers will be performed for each time point at which the each marker is determined. Response (CR/PR vs not) will be modeled as a function of a dichotomized version of pre-study the continuous (ungrouped) markers (e.g., TILs from tissue, and the Th1/Th2 cytokine ratio from serum). The statistical goal of these exploratory analyses is to obtain the point and 95% CI estimates of the OR, and to simply determine the direction and approximate magnitude of these associations for use in planning a subsequent study. Censored PFS will be modeled as a function of a dichotomized version of the continuous (ungrouped) markers (e.g., TILs from tissue, and the Th1/Th2 cytokine ratio using Cox modelling strategy.

Time frame:
Up to 12 months

No measurements were reported for this outcome.

Adverse events

Collected over All-cause mortality was assessed up to 36 months, and serious and Other (Not Including Serious) Adverse Events were assessed for up to 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Nivolumab, Radiation Therapy)13/20 (65%)11/20 (55%)19/20 (95%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventTreatment (Nivolumab, Radiation Therapy)
Lymphocyte count decreasedInvestigations4/20
Urinary tract infectionInfections and infestations3/20
AnemiaBlood and lymphatic system disorders2/20
DehydrationMetabolism and nutrition disorders2/20
Renal and urinary disorders - Other, specifyRenal and urinary disorders2/20
Generalized muscle weaknessMusculoskeletal and connective tissue disorders2/20
Alanine aminotransferase increasedInvestigations1/20
Aspartate aminotransferase increasedInvestigations1/20
Bladder infectionInfections and infestations1/20
DiarrheaGastrointestinal disorders1/20
Most frequent other events
Showing 10 of 73
Most frequent other events
EventTreatment (Nivolumab, Radiation Therapy)
FatigueGeneral disorders15/20
DiarrheaGastrointestinal disorders12/20
Urinary tract infectionInfections and infestations7/20
AnorexiaMetabolism and nutrition disorders6/20
Edema limbsGeneral disorders6/20
ConstipationGastrointestinal disorders5/20
Urinary frequencyRenal and urinary disorders5/20
AnemiaBlood and lymphatic system disorders4/20
DehydrationMetabolism and nutrition disorders4/20
Lymphocyte count decreasedInvestigations4/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment (Nivolumab, Radiation Therapy)
Median78.5 (54 to 95)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Nivolumab, Radiation Therapy)
Female5
Male15
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Nivolumab, Radiation Therapy)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White16
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment (Nivolumab, Radiation Therapy)
United States20
Performance Status
Performance Status(Participants)Treatment (Nivolumab, Radiation Therapy)
03
116
21
Pathological stage
Pathological stage(Participants)Treatment (Nivolumab, Radiation Therapy)
T2Nx: Clinically main tumor invades muscularis propria, Cancer in lymph nodes cannot be measured.6
pT2: Pathologically invades muscularis propria3
pT2N1: Pathologically invades muscularis propria with a single node in the true pelvis1
pT2Nx: Pathologically tumor invades muscularis propria, Cancer in lymph nodes not measurable.6
pT2b: Pathologically invades the outer half of the muscularis propria.2
pT4: Pathologically directly invades into adjacent structures.2
Prior Bacillus Calmette-Guerin (BCG) Therapy
Prior Bacillus Calmette-Guerin (BCG) Therapy(Participants)Treatment (Nivolumab, Radiation Therapy)
No15
Yes5
Prior Chemotherapy
Prior Chemotherapy(Participants)Treatment (Nivolumab, Radiation Therapy)
No17
Yes3
08

Study locations

2 sites
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Mar 2023, 58 months.

Results were first posted in Aug 2023, 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2018
First posted
Feb 5, 2018
StartActual
Apr 24, 2018
Primary completionActual
Mar 23, 2023
CompletionActual
Mar 23, 2023
Results first posted
Aug 4, 2023
Last update
Aug 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03421652
Responsible party
Nitin Vaishampayan, MD (Principal Investigator, Barbara Ann Karmanos Cancer Institute) — Principal investigator
First posted
Feb 5, 2018
Start date
Apr 24, 2018
Primary completion
Mar 23, 2023
Completion
Mar 23, 2023
Results posted
Aug 4, 2023
Last update
Aug 4, 2023

Study contacts

Ulka N. Vaishampayan, M.D.
principal investigator · Barbara Ann Karmanos Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion